CVD risk classification comparison using the JBSII, Framingham and QRISK2 algorithms: POCT (LDX and CardioChek) versus the laboratory methods
| Laboratory | Laboratory | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| LDX | ≤9.9% | 10–19% | ≥20% | Total | CardioChek | ≤9.9% | 10–19% | ≥20% | Total |
| (A) JBSII: Roche vs LDX | (D) JBSII: Roche vs CardioChek | ||||||||
| ≤9.9% | 72 (47.1) | 0 | 0 | 72 (47.1) | ≤9.9% | 39 (51.3) | 0 | 0 | 39 (51.3) |
| 10–19% | 7 (4.6) | 53 (34.6) | 0 | 60 (39.2) | 10–19% | 0 | 18 (23.7) | 3 (3.9) | 21 (27.6) |
| ≥20% | 0 | 4 (2.6) | 17 (11.1) | 21 (13.7) | ≥20% | 0 | 0 | 16 (21.0) | 16 (21.1) |
| Total | 79 (51.6) | 57 (37.2) | 17 (11.1) | 153 (100) | Total | 39 (51.3) | 18 (23.7) | 19 (25.0) | 76 (100) |
| (B) Framingham: Roche vs LDX | (E) Framingham: Roche vs CardioChek | ||||||||
| ≤9.9% | 94 (58.0) | 0 | 0 | 94 (58.0) | ≤9.9% | 41 (47.1) | 1 (1.2) | 0 | 42 (48.3) |
| 10–19% | 5 (3.1) | 44 (27.2) | 0 | 49 (30.3) | 10–19% | 0 | 14 (16.1) | 6 (6.9) | 20 (23.0) |
| ≥20% | 0 | 1 (0.6) | 18 (11.1) | 19 (11.7) | ≥20% | 0 | 0 | 25 (28.7) | 25 (28.7) |
| Total | 99 (61.1) | 45 (27.8) | 18 (11.1) | 162 (100) | Total | 42 (47.6) | 15 (17.1) | 31 (35.2) | 87 (100) |
| (C) QRISK2: Roche vs LDX | (F) QRISK2: Roche vs CardioChek | ||||||||
| ≤9.9% | 124 (76.5) | 1 (0.6) | 0 | 125 (77.1) | ≤9.9% | 48 (55.2) | 0 | 0 | 48 (55.2) |
| 10–19% | 0 | 27 (16.7) | 0 | 27 (16.7) | 10–19% | 2 (2.3) | 16 (18.3) | 0 | 18 (20.7) |
| ≥20% | 0 | 0 | 10 (6.2) | 10 (6.2) | ≥20% | 0 | 0 | 21 (24.1) | 21 (24.1) |
| Total | 124 (76.5) | 28 (17.3) | 10 (6.2) | 162 (100) | Total | 50 (57.4) | 16 (18.3) | 21 (24.1) | 87 (100) |
| JBSII | Framingham | QRISK2 | |
|---|---|---|---|
| (G) Overall CVD risk classification agreement | |||
| Agreement (%) | |||
| LDX | 142 (92.8) | 156 (96.3) | 161 (99.4) |
| CardioChek | 73 (96.1) | 80 (92.0) | 85 (97.7) |
| Disagreement (%) | |||
| LDX | 11 (7.2) | 6 (3.7) | 1 (0.6) |
| CardioChek | 3 (3.9) | 7 (8.0) | 2 (2.3) |
| Disagreement when laboratory CVD risk score >20% (%) | |||
| LDX | 0 (0) | 0 (0) | 0 (0) |
| CardioChek | 3 (3.9) | 6 (6.9) | 0 (0) |
Matrices shown in panels A–F show the number of subjects classified in the three CVD risk categories (≤9.9%, 10–19% and ≥20%) by each POCT analyser compared to the laboratory method with the percentage in parentheses; JBSII (panels A and D), Framingham (panels B and E) and QRISK2 (panels C and F). Panel G summarises the overall CVD risk agreement (ie, correct classification into the three CVD categories) of the POCT analysers with the laboratory methods including any high-risk subjects that were misclassified.
CVD, cardiovascular disease; POCT, point-of-care testing.